Form 4: RA Capital Management Reports Beneficial Ownership Changes in Sionna Therapeutics Following IPO

RA Capital Management and related entities report changes in beneficial ownership of Sionna Therapeutics common stock following the conversion of preferred stock in connection with the company's initial public offering.

Summary

• RA Capital Management, L.P., along with related funds and individuals, filed a Form 4 detailing changes in beneficial ownership of Sionna Therapeutics, Inc. (SION) common stock on February 10, 2025.
• The filing reflects the conversion of Series Seed, Series A, Series B, and Series C Preferred Stock into common stock at a ratio of 1-for-1.4611 upon the closing of Sionna Therapeutics' initial public offering (IPO).
• The reported transactions include the acquisition of common stock through the conversion of preferred stock and purchases of common stock at $18 per share.
• RA Capital Management, L.P. acts as the investment manager for RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus III Fund, L.P., and a separately managed account.
• Peter Kolchinsky and Rajeev Shah, managing members of RA Capital Management GP, LLC, disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard post-IPO transactions and continued investment by a major shareholder, suggesting confidence in the company's prospects.

Positives

• The conversion of preferred stock to common stock indicates a positive step towards a simplified capital structure for Sionna Therapeutics following its IPO.
• RA Capital's continued investment, including purchasing shares at $18, suggests confidence in Sionna's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the transactions indicate RA Capital's ongoing involvement and investment in Sionna Therapeutics.

Management Comments

• Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Industry Context

Form 4 filings are standard practice for major shareholders and insiders following significant transactions, particularly after an IPO. This filing provides transparency into the ownership structure of Sionna Therapeutics post-IPO.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for individuals and entities holding more than 10% of a company's shares, or who are directors or officers, as per the Securities Exchange Act of 1934.
• Similar filings are common for other biotech companies after an IPO, such as those made by venture capital firms in companies like Moderna or BioNTech, reflecting their initial investments and subsequent adjustments in ownership.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of the company.
• The continued investment by RA Capital may be viewed positively by the market.

Key Dates

Keywords

Sionna Therapeutics, RA Capital Management, beneficial ownership, Form 4, IPO, preferred stock, common stock, conversion